文献速递心境障碍

抑郁症治疗抵抗的全基因组关联研究及三个独立样本的荟萃分析

Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples.
PubMed 文献 · Br J Psychiatry · 2018-11-23

该研究基于欧洲抵抗性抑郁症研究组(GSRD)的1148例重性抑郁障碍(MDD)患者,以全基因组关联方法探索治疗抵抗抑郁症(TRD)的遗传预测因子,并与STAR*D(n=1316)和GENDEP(n=761)进行固定效应荟萃分析。未发现单个多态性或基因与TRD相关,但两个基因集(GO:0043949和GO:0000183)在GSRD及荟萃分析中与TRD相关(校正P=0.030和P=0.027)。

要点

  • 未发现单个基因或位点与治疗抵抗抑郁症显著相关。
  • 两个基因集与TRD相关,涉及cAMP信号和染色质沉默。
  • 这些基因集可能作为个性化抗抑郁治疗的候选生物标志物。

核心结论

  • 未发现单个多态性或基因与治疗抵抗抑郁症相关。
  • 两个基因集(GO:0043949和GO:0000183)在GSRD及荟萃分析中与TRD相关,校正P分别为0.030和0.027。
  • 所识别基因集涉及环磷酸腺苷介导的信号和染色质沉默,可能作为生物标志物或新药靶点。

研究设计与样本

  • 研究纳入GSRD队列的1148例重性抑郁障碍患者,使用Infinium PsychArray进行基因分型,定义TRD为对至少两种充分抗抑郁治疗无反应。
  • 比较TRD、应答者和首次抗抑郁治疗无应答者三组,在变异、基因和基因集水平进行遗传分析,采用加性回归模型。
  • 在GSRD参与者中进行固定效应荟萃分析,合并STAR*D(n=1316)和GENDEP(n=761)样本。

主要发现

  • 未发现单个多态性或基因与TRD显著相关,但一些提示性信号在细胞骨架调节、转录调节和钙信号通路中富集。
  • 基因集GO:0043949在GSRD中与TRD对比应答者相关,基因集GO:0000183在荟萃分析中与TRD对比应答和无应答者相关,校正P分别为0.030和0.027。

关键数值与推荐

  • TRD定义为对至少两种充分抗抑郁治疗缺乏反应。
  • 基因集GO:0043949与TRD对比应答者相关,校正P=0.030(GSRD)。
  • 基因集GO:0000183与TRD对比应答和无应答者相关,校正P=0.027(荟萃分析)。

临床怎么用

  • 所识别基因集涉及cAMP信号和染色质沉默,可能作为个性化抗抑郁治疗的潜在生物标志物。
  • 这些基因集可能作为新抗抑郁药物的研发靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment-resistant depression (TRD) is the most problematic outcome of depression in terms of functional impairment, suicidal thoughts and decline in physical health.AimsTo investigate the genetic predictors of TRD using a genome-wide approach to contribute to the development of precision medicine. METHOD: A sample recruited by the European Group for the Study of Resistant Depression (GSRD) including 1148 patients with major depressive disorder (MDD) was characterised for the occurrence of TRD (lack of response to at least two adequate antidepressant treatments) and genotyped using the Infinium PsychArray. Three clinically relevant patient groups were considered: TRD, responders and non-responders to the first antidepressant trial, thus outcomes were based on comparisons of these groups. Genetic analyses were performed at the variant, gene and gene-set (i.e. functionally related genes) level. Additive regression models of the outcomes and relevant covariates were used in the GSRD participants and in a fixed-effect meta-analysis performed between GSRD, STAR*D (n = 1316) and GENDEP (n = 761) participants. RESULTS: No individual polymorphism or gene was associated with TRD, although some suggestive signals showed enrichment in cytoskeleton regulation, transcription modulation and calcium signalling. Two gene sets (GO:0043949 and GO:0000183) were associated with TRD versus response and TRD versus response and non-response to the first treatment in the GSRD participants and in the meta-analysis, respectively (corrected P = 0.030 and P = 0.027). CONCLUSIONS: The identified gene sets are involved in cyclic adenosine monophosphate mediated signal and chromatin silencing, two processes previously implicated in antidepressant action. They represent possible biomarkers to implement personalised antidepressant treatments and targets for new antidepressants.Declaration of interestD.S. has received grant/research support from GlaxoSmithKline and Lundbeck; has served as a consultant or on advisory boards for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen and Lundbeck. S.M. has been a consultant or served on advisory boards for: AstraZeneca, Bristol-Myers Squibb, Forest, Johnson & Johnson, Leo, Lundbeck, Medelink, Neurim, Pierre Fabre, Richter. S.K. has received grant/research support from Eli Lilly, Lundbeck, Bristol-Myers Squibb, GlaxoSmithKline, Organon, Sepracor and Servier; has served as a consultant or on advisory boards for AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Lundbeck, Pfizer, Organon, Schwabe, Sepracor, Servier, Janssen and Novartis; and has served on speakers' bureaus for AstraZeneca, Eli Lily, Lundbeck, Schwabe, Sepracor, Servier, Pierre Fabre, Janssen and Neuraxpharm. J.Z. has received grant/research support from Lundbeck, Servier, Brainsway and Pfizer, has served as a consultant or on advisory boards for Servier, Pfizer, Abbott, Lilly, Actelion, AstraZeneca and Roche and has served on speakers' bureaus for Lundbeck, Roch, Lilly, Servier, Pfizer and Abbott. J.M. is a member of the Board of the Lundbeck International Neuroscience Foundation and of Advisory Board of Servier. A.S. is or has been consultant/speaker for: Abbott, AbbVie, Angelini, Astra Zeneca, Clinical Data, Boehringer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Innovapharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi and Servier. C.M.L. receives research support from RGA UK Services Limited.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Fabbri C, Kasper S, Kautzky A, et al. Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. Br J Psychiatry. 2018. PMID: 30468137. doi:10.1192/bjp.2018.256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。